| Active, not recruiting | 3 | 516 | Europe | BCG, Bacillus Calmette Guerin (BCG) Medac®, OncoTice, Atezolizumab, MPDL3280A, Tecentriq® | UNICANCER, Hoffmann-La Roche | Bladder Cancer | 10/24 | 10/28 | | |
iNDUCT, NCT04617756: Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract |
|
|
| Recruiting | 2 | 50 | Europe | Patients receiving neoadjuvant therapy before radical nephrectomy | Centre Hospitalier Universitaire de Nīmes, Pitié-Salpêtrière Hospital, Hôpital Bichat-Claude Bernard, 75018 Paris, Hopital Foch 92151 Suresnes, Institut Paoli-Calmettes, European Georges Pompidou Hospital, Saint-Louis Hospital, Paris, France, Centre Hospitalier Lyon Sud, Center Eugene Marquis, IUCT ONCOPOLE | Urothelial Carcinoma, Cancer | 01/25 | 10/26 | | |
| Active, not recruiting | N/A | 280 | Europe | Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy, Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy | University Hospital, Bordeaux | Kidney Tumors Treated With Minimally Invasive Surgery | 04/24 | 05/24 | | |
| Recruiting | N/A | 30000 | Europe, RoW | Radical nephrectomy versus partial nephrectomy (according surgeon judgement) | University Hospital, Bordeaux | Kidney Cancer | 12/40 | 12/40 | | |
